Compare Acadia Healthcare Company Inc (ACHC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Incyte Corporation — how do they compare? Acadia Healthcare Company Inc trades at $31.18 (market cap $2.90B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 8.5× Acadia Healthcare Company Inc's market cap. Which is the better fit depends on your goals.
| ACHC | INCY | |
|---|---|---|
Market Cap | $2.90B | $24.54B |
Sector | Health | Health |
52-Week High | $35.61 | $129.93 |
52-Week Low | $11.68 | $81.61 |
Enterprise Value | $5.29B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.70, down 0.25% on the day, with neutral technical indicators and strong analyst support (68% buy ratings). The company has beaten earnings estimates for three consecutive quarters, though profitability remains challenged with a -33.44% net income margin. Recent Q2 2026 results showed revenue of $865.8 million with earnings beating expectations at $0.38 per share.
While facing profitability challenges and ongoing legal investigations, ACHC benefits from strong analyst consensus with a $36.00 price target representing 13.6% upside. The stock offers potential through continued earnings beats and operational improvements, but investors must weigh legal risks against the company's turnaround strategy and behavioral healthcare demand growth.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
